Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Sectoral/ Thematic median (250 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 11 Nov 2021 – 20 Aug 2026, limited by ITI Pharma and Healthcare Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | ITI Pharma and Healthcare Fund | Nifty 500 |
|---|---|---|
| 11 Nov 2021 | ₹100.00 | ₹100.00 |
| 05 Apr 2022 | ₹97.37 | ₹99.87 |
| 29 Aug 2022 | ₹92.35 | ₹97.16 |
| 21 Jan 2023 | ₹96.01 | ₹99.59 |
| 15 Jun 2023 | ₹103.28 | ₹104.20 |
| 07 Nov 2023 | ₹115.29 | ₹111.53 |
| 01 Apr 2024 | ₹144.01 | ₹132.97 |
| 24 Aug 2024 | ₹171.63 | ₹151.96 |
| 16 Jan 2025 | ₹173.93 | ₹140.90 |
| 10 Jun 2025 | ₹174.17 | ₹151.45 |
| 03 Nov 2025 | ₹178.69 | ₹154.50 |
| 28 Mar 2026 | ₹163.27 | ₹136.40 |
| 20 Aug 2026 | ₹198.11 | ₹152.57 |
| Metric | ITI · Direct · IDCW NAV ₹19.82 Very High risk ★★★★★ | Category median Sectoral/ Thematic · 250 funds |
|---|---|---|
| +12.31% | +5.11% | |
| +20.19% | +13.02% | |
| — | +11.14% | |
| — | +12.26% | |
| +15.40% | +11.82% | |
| +18.86% | — | |
| +21.95% | +14.62% | |
| — | +12.95% | |
| — | +13.24% | |
| Risk | ||
| 14.15% | 15.88% | |
| 0.97 | 0.35 | |
| 1.35 | 0.47 | |
| -17.69% | -25.18% | |
| Nifty 500 | — | |
| +8.93% | +1.40% | |
| 0.80 | 0.98 | |
| 112.9% | 101.5% | |
| 71.0% | 97.0% | |
| 0.92% | 1.14% | |
| ₹233.89Cr | ₹1,162Cr | |
| 0.50% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 53% | 45% | |
| Rajesh Bhatia | — | |
| 11 Nov 2021 | — | |
| 37 | — | |
| 58.2% | — | |
| 3.2% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.